VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

Annogen to develop multiple CNS-cell specific promoters for VectorY programs

AMSTERDAM--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE^™ technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY’s vectorized antibody programs.

Using its proprietary Survey of Regulatory Elements (SuRE^™) technology, Annogen functionally annotates the entire human non-coding genome to identify regulatory DNA elements that control therapeutic gene expression for gene & cell therapy. Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner. The SuRE^™ technology is unique among other promoter-identification technologies in functionally testing non-coding promoter elements throughout the entire genome, including at remote sites where activity is regulated.

“We are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY’s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative diseases such as ALS”, Sander van Deventer CEO of VectorY said.

VectorY is a leader in the development of transformative vectorized antibody therapies for neurodegenerative diseases with high unmet medical need. With extensive internal knowhow, a unique proprietary platform has been assembled that combines state-of-the-art therapeutic antibodies, capsids, and manufacturing to enable efficient delivery of one-time precision treatments to the CNS. VectorY is advancing a pipeline of potentially disease-modifying treatments for devastating neurodegenerative diseases, including ALS, Huntington’s, and Parkinson’s disease.

“VectorY is a leading example of novel advanced approaches to vectorized antibody therapy development,” Joris van Arensbergen CEO of Annogen adds. “Their focus on controlling various aspects of vector design, including cell-specific promoters, proves the value we can bring with our SuRE^™ technology. We are very pleased to work with this forward-thinking team and further build our track record in this field.”

-Ends-

About VectorY
VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington’s disease. For more information, see www.vectorytx.com.

About Annogen
At Annogen we use our SuRE^™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein production. In addition, we offer the AIM^™ service to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches enables Research and Development to qualitatively interpret the non-coding genome in humans, animals and plants. For more information, please visit www.annogen.bio.

Contacts

VectorY Therapeutics B.V.
Sariette Witte, Head of Communications
E-mail: sariette.witte@vectorytx.com
Tel: +31 681 174 072

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell / Giulia Lasagni / Manisha Kuttetira
E-mail: VectorY@instinctif.com
Tel: +44 20 7457 2020

Annogen
P. Victor Schut, CBO
victor@annogen.bio

Liked what you read? Head to the TechDogs homepage to find the latest tech content infused with drama and entertainment. We've got Articles, White Papers, Case Studies, Reports, Videos, Tech News and Events - the complete lot to help you Know Your World of Technology.

First published on Thu, Jan 19, 2023

Liked what you read? That’s only the tip of the tech iceberg!

Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!

Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.

Dive into TechDogs' treasure trove today and Know Your World of technology like never before!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs' site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.

Tags:

VectorY Annogen SuRE™ Technology Biotech Company Gene & Cell Therapy

Join The Discussion

BioTechnology

VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters

Join Our Newsletter